Condition: Myelofibrosis · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the safety of the drug in these patients after a single dose.
This description comes directly from the study's public registry record.
Wei Zhao, Doctor · 0531-85875449 · zhao4wei2@hotmail.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang, Henan, China | Recruiting |
| The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital) | Jinan, Shandong, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07480824